Managing Your Digical Ulcer PDF Print E-mail
Thursday, 19 August 2010 12:49
Around 40% of patients with Scleroderma develop open sores on their fingertips called digital ulcers. In some patients, this is the major ongoing difficulty whereas in others, digital ulcers are an uncommon and short term complication.

Digital ulcers occur because of poor blood flow to the fingertips which is in turn related to the narrowing of blood vessels that is the hallmark of all forms of Systemic Scleroderma.

Digital ulcers are tightly linked with Raynaud's phenomenon. They both occur in Scleroderma because of narrowed blood vessels. Raynaud attacks occur daily and are clearly worsened by cold weather. Digital ulcers can occur at anytime of the year and in any weather.

The fingertips in Scleroderma should be cared for in much the way a patient with diabetes might care for their feet.
  • Keep the skin moist and supple. Hand creams rich in lanolin can help.
  • Protect the fingertips. Avoid tasks that risk fingertip trauma.
  • Treat cuts promptly and thoroughly. Don’t let infection get established.
  • Control your Raynaud’s phenomenon more effectively. This requires working closely with your physician to choose the best program of medication.
  • Keep your physician involved. Let him or her know when an ulcer has started. The earlier it is treated, the better the outcome.

The Scleroderma research community is actively investigating treatments for digital ulcers. In Europe, intravenous iloprost (Ilomedin®) is approved and widely used, although this therapy is not available in the U.S. Recent studies with bosentan (Tracleer®), an agent approved by the FDA for pulmonary hypertension, have suggested an effect in preventing digital ulcers. Other research projects are in early stages of planning.

Source: University of Michigan Health System
 
More articles :

» Methotrexate Effective In Juvenile Localized Scleroderma

is effective in when given with a short course of steroids, an Italian randomized study confirmed.Among children ages 6 to 17 receiving methotrexate, 67.4% completed the yearlong trial without flaring, compared with 29.2% of those given placebo...

» A Scleroderma Fact Sheet

Below, is a very useful fact sheet on Scleroderma. Making for much easier reading and reference, this fact sheet highlights what Scleroderma is, how is it diagnosed, who gets it, complications which may arise, and how it can be treated. Feel free to...

» PDE-5 Inhibitors in Scleroderma Raynaud Phenomenon and Digital Ulcers: Current Status of Clinical Trials

Ann J. Impens, Kristine Phillips, and Elena SchiopuReceived 2 June 2011; Accepted 2 August 2011Phosphodiesterases (PDEs) are isoenzymes that control the level of intracellular cyclic guanosine monophosphate (cGMP) and cyclic adenosine monophosphate...

» Special Surgery Scientists To Share Advances in Lupus and Related Conditions

Hospital for Special Surgery physicians who focus on lupus, scleroderma and related conditions are traveling from New York City to Atlanta this week to share their recent findings at the 74th Annual Scientific Meeting of the American College of...

» Role of N-terminal Brain Natriuretic Peptide in Scleroderma-associated Pulmonary Arterial Hypertension

Mark H. Williams, Clive E. Handler, Raza Akram, Colette J. Smith, Clare Das, Joanna Smee, Devaki Nair, Christopher P. Denton, Carol M. Black and John G. CoghlanFirst published online: April 27, 2006Source:

» New Promising Therapy Against Systemic Sclerosis

There is a new path to defeat systemic sclerosis, also called because of the hardening of the skin of the patients (from Greek skleros, "hard", and derma, "skin"). This path involves the B-cell of the immune system, so far only considered "innocent...